# Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by FDG-PET and Molecular Markers

> **NCT02600442** · — · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 168 (estimated)

## Conditions studied

- Breast Neoplasms
- Breast Cancer

## Interventions

- **OTHER:** non interventional study

## Key facts

- **NCT ID:** NCT02600442
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-07
- **Primary completion:** 2016-12
- **Final completion:** 2020-12
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2016-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02600442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02600442, "Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by FDG-PET and Molecular Markers". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02600442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*